List of Excipients in Branded Drug GLYCOPYRROLATE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merz Pharmaceuticals LLC	GLYCOPYRROLATE	glycopyrrolate	0259-0502	CITRIC ACID MONOHYDRATE
Merz Pharmaceuticals LLC	GLYCOPYRROLATE	glycopyrrolate	0259-0502	GLYCERIN
Merz Pharmaceuticals LLC	GLYCOPYRROLATE	glycopyrrolate	0259-0502	METHYLPARABEN

Generic Drugs Containing GLYCOPYRROLATE

Company	Ingredient	NDC	Excipient
West-ward Pharmaceutical Corp	glycopyrrolate	0143-1250	ANHYDROUS LACTOSE
West-ward Pharmaceutical Corp	glycopyrrolate	0143-1250	CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
West-ward Pharmaceutical Corp	glycopyrrolate	0143-1250	LACTOSE MONOHYDRATE

What are the Most Frequently-Used Excipients in GLYCOPYRROLATE?

# Of NDCs	Excipient
3	ANHYDROUS CITRIC ACID
12	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
11	ANHYDROUS LACTOSE

Glycopyrrolate Excipient Strategy and Commercial Opportunities

Last updated: September 30, 2026

Glycopyrrolate has a fragmented product market spanning tablets, oral solutions, injections, dry-powder inhalers, nebulized suspensions and fixed-dose inhaled combinations. The strongest excipient opportunities are in pediatric oral liquids, inhalation products, preservative-free parenterals and differentiated combination products. Excipient selection can improve tolerability, dose uniformity, device performance and regulatory substitutability, but it rarely creates durable exclusivity by itself.

What pharmaceutical formulations contain glycopyrrolate?

Glycopyrrolate, also called glycopyrronium bromide in some markets, is a quaternary ammonium antimuscarinic. Its permanent positive charge limits passive central nervous system penetration and supports local respiratory delivery. The drug is used for secretion control, perioperative anticholinergic treatment and maintenance bronchodilation in chronic obstructive pulmonary disease.

Product or product type	Route	Typical commercial role	Excipient strategy
Glycopyrrolate tablets	Oral	Anticholinergic treatment	Conventional tablet fillers, binders and lubricants
Cuvposa	Oral solution	Pediatric chronic drooling and secretion control	Palatability, pH control, aqueous stability
Glycopyrrolate injection	Intravenous or intramuscular	Perioperative use	Sterility, isotonicity, preservative control
Seebri Neohaler	Dry-powder inhalation	COPD maintenance	Lactose carrier and inhaler capsule performance
Lonhala Magnair	Nebulized inhalation	COPD maintenance	Aqueous inhalation solution and nebulizer compatibility
Bevespi Aerosphere	Metered-dose inhaler	Glycopyrrolate/formoterol COPD treatment	Suspension stability, propellant and device compatibility
Utibron Neohaler	Dry-powder inhalation	Indacaterol/glycopyrrolate COPD treatment	Carrier-based powder engineering
Breztri Aerosphere	Metered-dose inhaler	Budesonide/glycopyrrolate/formoterol COPD treatment	Triple-drug suspension and aerosol performance

The product-specific excipient profile is controlled by the approved labeling and chemistry, manufacturing and controls documentation. FDA labeling identifies lactose, magnesium stearate, citric acid, sodium citrate, sweeteners, flavoring agents and water-based vehicles in relevant products, although the precise composition differs by dosage form and manufacturer (U.S. Food and Drug Administration [FDA], 2010, 2015, 2016, 2017, 2020).

Which glycopyrrolate dosage forms offer the largest commercial opportunity?

The highest-value opportunities are differentiated oral liquids and inhaled products rather than standard tablets.

Pediatric oral liquids

Cuvposa was approved in the United States in 2010 for chronic severe drooling associated with neurologic conditions in children. The product is administered according to weight, making dose measurement and palatability commercially important.

A competitive oral-liquid platform can target:

• Sugar-free and alcohol-free formulations
• Reduced sodium content
• Improved flavor masking
• Lower viscosity for oral syringes
• Better chemical stability after opening
• Unit-dose packaging for institutional use
• Pediatric dosing in smaller volume increments
• Preservative-free packaging where microbiological control permits

Glycopyrrolate is bitter, and its anticholinergic effects can complicate adherence. Taste masking should focus on bitterness suppression rather than simply increasing sweetness. Ion-pairing, polymeric taste blockers, flavor systems and pH optimization may support differentiation, but each approach requires assessment of assay, dissolution, dose uniformity and stability.

A pediatric product also needs a dosing device strategy. An oral syringe calibrated for weight-based dosing can reduce administration error and create a combination-product or device-related differentiation point. The formulation should maintain uniform concentration throughout the labeled shelf life and after repeated opening.

Inhaled dry powders

Dry-powder glycopyrrolate products generally use carrier-based powder systems. Lactose is a common inhalation carrier because it supports powder handling and dose metering. The commercial challenge is not merely selecting lactose. It is controlling particle-size distribution, surface morphology, moisture, fine-particle fraction and capsule emptying.

Potential development strategies include:

• Engineered lactose with controlled fines
• Spray-dried or spray-freeze-dried glycopyrrolate particles
• Carrier-free particles
• Amino-acid or phospholipid surface modification
• Moisture-resistant packaging
• Lower-resistance inhaler platforms
• Improved dose consistency across inspiratory-flow rates

For a generic dry-powder inhaler, the excipient system cannot be evaluated separately from the inhaler. FDA approval requires a product that is pharmaceutically equivalent and therapeutically equivalent under the applicable pathway. Device resistance, emitted dose, aerodynamic particle-size distribution and patient-use performance can become significant development barriers.

Nebulized solutions

Lonhala Magnair uses glycopyrrolate delivered through a nebulizer system. Nebulized solutions offer an opportunity for patients who cannot reliably generate the inspiratory flow required by some dry-powder devices.

Commercially relevant formulation targets include:

• Preservative-free sterile solution
• Low osmolality burden
• Controlled pH
• Minimal residual volume
• Reduced foaming
• Short administration time
• Compatibility with reusable or disposable nebulizers
• Low extractables and leachables risk

For nebulized glycopyrrolate, excipient simplicity is generally valuable. Surfactants, preservatives and complex co-solvent systems may increase pulmonary tolerability, toxicology and device-compatibility burdens. A sterile, isotonic or near-isotonic aqueous formulation with robust container closure performance is generally easier to position than a chemically complex alternative.

What excipients are relevant to glycopyrrolate oral formulations?

Oral tablets

Conventional tablet opportunities are primarily cost and supply-chain driven. Useful excipient changes may include:

• Direct-compression filler systems
• Low-moisture formulations
• Improved hardness without delayed disintegration
• Reduced tablet size
• Film coating for taste and handling
• Lactose-free or low-lactose alternatives
• Robust packaging for high-humidity markets

The active ingredient is administered at relatively low strength, so blend uniformity is central. Low-dose content uniformity can favor ordered mixing, engineered excipients or granulation approaches. A formulation change that improves manufacturability without changing release behavior may support a differentiated generic or a 505(b)(2) product, depending on the proposed labeling and clinical claims.

Oral solutions

The main excipient variables are pH, buffering capacity, sweetener system, flavor, viscosity and preservative approach.

Formulation objective	Candidate strategy	Primary technical risk
Bitterness reduction	Flavor modulation, polymeric taste masking	Reduced dose accuracy or precipitation
Chemical stability	Citrate or alternative buffer system	pH-dependent degradation
Pediatric acceptability	Noncariogenic sweeteners and fruit flavors	Flavor instability or allergen concerns
Dose measurement	Low-viscosity aqueous vehicle	Spillage and inaccurate administration
Preservative-free presentation	Unit-dose or validated multidose closure	Microbial contamination
Global market access	Sugar-free and alcohol-free vehicle	Lower solubility or palatability

The most defensible commercial position is usually a complete product platform: formulation, dosing device, packaging and patient-use data. An excipient-only claim is less likely to block competitors than a formulation combined with a specific concentration, pH range, container or administration system.

What excipients are used in inhaled glycopyrrolate products?

Dry-powder inhalers

Lactose-based carrier systems are common, but they create several design constraints. Glycopyrrolate must remain adequately dispersed from the carrier during inhalation. Excessive carrier adhesion can lower fine-particle delivery. Excessive detachment can create dose variability and device-retention problems.

Key control variables are:

1. Active particle size and morphology.
2. Carrier particle-size distribution.
3. Fine lactose content.
4. Relative humidity exposure.
5. Powder electrostatics.
6. Capsule puncture and emptying.
7. Inhaler airflow resistance.
8. Emitted dose and aerodynamic particle-size distribution.

A proprietary carrier treatment or inhaler geometry may provide stronger protection than a basic lactose substitution. The same excipient platform may also support lifecycle expansion into glycopyrrolate combinations with formoterol, indacaterol or inhaled corticosteroids.

Metered-dose inhalers

Bevespi Aerosphere and Breztri Aerosphere use pressurized metered-dose inhaler technology. In these products, the formulation depends on a suspended drug system, propellant behavior, valve metering and actuator performance.

Commercial opportunities include:

• Improved suspension homogeneity
• Reduced settling or creaming
• Lower valve retention
• More consistent emitted dose
• Lower throat deposition
• Reduced actuator deposition
• Improved stability during temperature cycling
• Alternative propellant strategies

The transition from older hydrofluoroalkane propellants to lower-global-warming-potential propellants creates a major platform opportunity. Any reformulation must preserve dose delivery, particle size, device function and clinical performance. A propellant change can require substantial comparative characterization and, depending on the product and regulatory strategy, clinical bridging.

What patent protection can cover glycopyrrolate formulations?

Glycopyrrolate itself is an established active ingredient, so commercial protection is more likely to arise from product architecture than from basic composition-of-matter rights.

Formulation patents

Potential claim categories include:

• Specific glycopyrrolate concentrations
• Defined pH or buffer ranges
• Stabilized aqueous solutions
• Preservative-free formulations
• Taste-masked oral liquids
• Specific lactose carrier distributions
• Spray-dried or engineered particles
• Propellant-based suspensions
• Container closure systems
• Nebulizer-compatible formulations
• Moisture-protective packaging

Formulation patents are strongest when the claimed composition is linked to measurable performance, such as improved stability, reduced variability or superior pulmonary deposition. Broad claims covering routine excipient substitution are more vulnerable to written-description, enablement and obviousness challenges.

Method-of-use patents

Glycopyrrolate method-of-use protection may cover:

• Chronic drooling in defined pediatric populations
• COPD maintenance treatment
• Specific dosing schedules
• Use through a particular delivery device
• Combination treatment with a long-acting beta agonist or inhaled corticosteroid
• Reduction of exacerbations or improvement in lung function

Method-of-use patents can remain commercially relevant after composition patents expire, but enforcement depends on label language, induced-infringement evidence and the actual conduct of generic manufacturers.

Device and combination-product patents

For inhaled products, the commercially relevant patent estate may include:

• Inhaler airflow paths
• Capsule handling
• Metering valves
• Actuators
• Nebulizer components
• Dose counters
• Drug-device interfaces
• Formulation-device combinations

These rights can be more difficult to design around than a single excipient patent because the product must meet both pharmaceutical and device performance requirements.

What is the FDA Orange Book status of glycopyrrolate products?

The Orange Book identifies approved drug products, therapeutic-equivalence evaluations and, where applicable, listed patents and exclusivity information. Glycopyrrolate products must be assessed individually by NDA, dosage form, route and reference product. A single conclusion for "glycopyrrolate" is not accurate because oral, injectable and inhaled products have separate regulatory records (FDA, 2024a).

Regulatory issue	Commercial implication
Listed drug status	Determines the reference product for an ANDA
Orange Book patents	Can trigger Paragraph IV certification and litigation
Method-of-use listings	May allow a skinny-label generic strategy
Inhaler reference product	Requires complex product and device comparison
Exclusivity	Can delay ANDA approval even when patents are absent
505(b)(2) pathway	May support reformulated or new-delivery glycopyrrolate products

An ANDA applicant challenging an Orange Book-listed patent may submit a Paragraph IV certification. The NDA holder can file suit within 45 days, triggering a statutory stay of FDA approval of up to 30 months, subject to statutory exceptions and case-specific outcomes under the Hatch-Waxman framework.

When does glycopyrrolate lose exclusivity?

Glycopyrrolate exclusivity is product-specific. The original active ingredient is old, but individual formulations and combination inhalers may have later patent and regulatory dates.

The relevant analysis should separate:

• Active-ingredient age
• NDA approval date
• New chemical entity exclusivity, if applicable
• Pediatric exclusivity
• Orphan-drug exclusivity, where applicable
• Orange Book patent expiration
• Patent-term adjustment or extension
• Regulatory exclusivity for new dosage forms
• Device and formulation patents
• Litigation-related approval stays

Key U.S. glycopyrrolate milestones include:

Product	Sponsor or commercial holder	FDA milestone
Cuvposa oral solution	Shionogi-related product history	Approved in 2010
Seebri Neohaler	Novartis	Approved in 2015
Utibron Neohaler	Novartis	Approved in 2015
Bevespi Aerosphere	AstraZeneca	Approved in 2016
Lonhala Magnair	Theravance Biopharma and partners	Approved in 2017
Breztri Aerosphere	AstraZeneca	Approved in 2020

These dates do not determine patent expiration. Patent expiration requires review of the relevant U.S. patent, terminal disclaimers, patent-term adjustment and any patent-term extension. FDA’s Orange Book and the USPTO Patent Center are the controlling sources for current status.

Which companies compete in glycopyrrolate products?

The competitive landscape includes branded respiratory companies, generic manufacturers and contract development organizations.

Branded competition

• AstraZeneca: Bevespi Aerosphere and Breztri Aerosphere
• Novartis: Seebri Neohaler and Utibron Neohaler
• Theravance Biopharma and commercial partners: Lonhala Magnair
• Shionogi-associated product history: Cuvposa

Generic and platform competition

Generic companies can compete in:

• Tablets
• Oral solutions
• Injection
• Dry-powder inhalers
• Inhaled fixed-dose combinations

The highest barrier is generally the inhaled combination market. Generic applicants must address product sameness, device performance, aerodynamic delivery and, in some cases, complex clinical or comparative requirements. Standard oral and injectable glycopyrrolate products generally present lower technical barriers, although low-dose uniformity and sterile manufacturing remain important.

What licensing opportunities exist for glycopyrrolate?

Licensing opportunities are most credible in delivery technology and combination products.

Potential transaction structures include:

• In-licensing a pediatric oral-liquid platform
• Acquiring a preservative-free nebulized formulation
• Licensing a low-global-warming-potential inhaler platform
• Co-developing glycopyrrolate with a long-acting beta agonist
• Licensing a carrier-engineered dry-powder system
• Out-licensing regional rights for generic or branded products
• Contract-manufacturing agreements for sterile solution or inhalation products

A licensee should evaluate ownership of formulation patents, freedom to operate on device components, manufacturing know-how, regulatory data rights, stability data and rights to improvements. The most valuable know-how may be unpublished process information rather than an excipient claim.

How strong is the glycopyrrolate patent estate?

The estate is strongest around branded inhaled combinations, proprietary inhalers and formulation-device systems. It is weaker around conventional oral tablets and basic glycopyrrolate solutions because the active ingredient and common excipients are established.

Product segment	Patent strength	Main barrier
Conventional tablets	Low to moderate	Limited formulation differentiation
Oral solution	Moderate	Taste, stability and dosing-device claims
Injection	Low to moderate	Sterile manufacturing and supply reliability
Dry-powder inhaler	Moderate to strong	Device, carrier and aerodynamic performance
Nebulized solution	Moderate	Device compatibility and sterile formulation
Dual-combination inhaler	Stronger	Combination, device and formulation claims
Triple-combination inhaler	Stronger	Multiple active ingredients and device system

What generic launch scenarios exist?

A generic launch strategy can follow several paths:

1. Early paragraph IV challenge: Appropriate where Orange Book patents are vulnerable and market size justifies litigation.
2. At-risk launch: Offers earlier revenue but exposes the applicant to damages and injunction risk.
3. Skinny-label launch: Removes patented method-of-use indications while retaining nonprotected uses.
4. Post-expiration launch: Lower litigation risk but may face multiple competitors.
5. 505(b)(2) reformulation: Targets improved taste, delivery, dosing or tolerability rather than direct substitution.
6. Device-specific generic launch: Potentially attractive in inhalation, but technically demanding.

Revenue exposure is highest for fixed-dose inhalers with multiple indications and established COPD market access. A generic that launches only after core combination patents expire may still encounter device patents, supply constraints and payer substitution barriers.

What are the geographic opportunities for glycopyrrolate?

The U.S. market has the clearest Orange Book and Paragraph IV framework. Europe and other major markets require separate review of national validation, supplementary protection certificates, centralized or decentralized marketing authorizations, device requirements and local substitution rules.

Regional opportunities include:

• Pediatric oral liquids in markets with limited ready-to-use products
• Preservative-free injections in hospital channels
• Generic inhalation products in countries with reference-product substitution
• Low-cost nebulized products where dry-powder inhalers have lower penetration
• Reformulated inhalers using lower-emission propellants
• Contract manufacturing for emerging markets

A global excipient strategy should avoid unnecessary reliance on excipients with complex regional status, variable compendial specifications or limited inhalation precedent.

Key Takeaways

• Glycopyrrolate has commercial opportunity across oral, injectable, nebulized and inhaled products.
• Pediatric oral liquids offer the clearest excipient-led differentiation through taste, stability and dosing accuracy.
• Inhaled products offer higher revenue potential but require integrated formulation-device development.
• Lactose carrier engineering, moisture control and aerodynamic performance are central to dry-powder products.
• Preservative-free sterile solutions are attractive for both oral and inhaled delivery where packaging can support microbiological control.
• Patent strength is concentrated in inhaler devices, fixed-dose combinations, formulations and method-of-use claims.
• Conventional tablets and injections are more exposed to generic competition.
• Orange Book status, patent-term calculations and Paragraph IV risk must be reviewed by individual product and dosage form.
• Licensing value is highest in delivery platforms, combination inhalers and pediatric administration systems.
• Excipient substitution alone rarely creates durable market exclusivity without associated performance, device or manufacturing claims.

FAQs

Can glycopyrrolate be formulated as a sugar-free pediatric liquid?

Yes. A sugar-free aqueous formulation can use noncariogenic sweeteners, flavor systems and pH control. The main development risks are bitterness, chemical stability, dose uniformity and microbial control.

Is lactose essential in glycopyrrolate dry-powder inhalers?

No. Lactose is a common carrier, but alternative carriers and carrier-free engineered particles are possible. Any substitute must meet inhalation performance, safety, stability and device requirements.

Can a new glycopyrrolate formulation qualify for a 505(b)(2) application?

Potentially. A new delivery route, formulation, dosage form or dosing system may support a 505(b)(2) strategy if the proposed application relies partly on FDA findings for an approved glycopyrrolate product and satisfies applicable bridging requirements.

What is the main barrier to a generic glycopyrrolate inhaler?

The main barrier is integrated product performance. The applicant must address formulation sameness, emitted dose, aerodynamic particle-size distribution, device operation, stability and, where applicable, comparative clinical requirements.

Do excipient patents protect glycopyrrolate products after active-ingredient patents expire?

They can, but only if the claims are valid, enforceable and commercially relevant to the marketed product. The strongest claims usually connect excipient composition with a defined performance result, device configuration or manufacturing process.

References

1. U.S. Food and Drug Administration. (2010). Cuvposa (glycopyrrolate) oral solution prescribing information.
2. U.S. Food and Drug Administration. (2015). Seebri Neohaler (glycopyrrolate inhalation powder) prescribing information.
3. U.S. Food and Drug Administration. (2015). Utibron Neohaler (indacaterol/glycopyrrolate) prescribing information.
4. U.S. Food and Drug Administration. (2016). Bevespi Aerosphere (formoterol fumarate/glycopyrrolate) prescribing information.
5. U.S. Food and Drug Administration. (2017). Lonhala Magnair (glycopyrrolate) prescribing information.
6. U.S. Food and Drug Administration. (2020). Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) prescribing information.
7. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book.
8. U.S. Food and Drug Administration. (2024b). Draft guidance for industry: Metered dose inhaler and dry powder inhaler drug products.
9. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary.